계명대학교 의학도서관 Repository

방광암 환자에서 BCG를 이용한 면역요법연구

Metadata Downloads
Author(s)
박철희이성준
Keimyung Author(s)
Park, Choal HeeLee, Sung Joon
Department
Dept. of Urology (비뇨의학)
Journal Title
Keimyung Medical Journal
Issued Date
1988
Volume
7
Issue
1
Abstract
Intravesical bacillus Calmette-Guerin (BCG) has been shown to be effective therapy and prophylaxis against recurrent tumor in patients with superficial bladder cancer (stages O and A), including carcinoma in situ. Tice-Chicago strain BCG was used to treat superficial transitional cell carcinoma of the bladder in 24 patients between July, 1985 and June, 1987. A variety of different BCG treatment regimens have been used that vary in intensity. In general, treatment results have been more favorable with intensive regimens. However, the toxicity also has been subustantially greater with intensive regimens. The optimal regimen has yet to be determined. Our treatment regimen of 120mg. Tice-Chicago strain BCG weekly for 6 weeks and then monthly for 3 months was well tolerated. 23 patients had a complete response and one had a tumor recurrence at 18 months follow-up, resulting in 96%of response rate. Side effects during of shortly after treatment were minor and self-limiting in the majority of patients (fever, bladder irritability and hematuria). This experience supports the efficacy of BCG as a cost effective, well-tolerated treatment modality for patients with superficial transitional cell carcinoma of the bladder.
Alternative Title
Therapy of BCG (bacillus Calmette-Guerin) for Superficial Transitional Cell Carcinoma of the Bladder
Keimyung Author(s)(Kor)
박철희
이성준
Publisher
Keimyung University School of Medicine
Citation
박철희 and 이성준. (1988). 방광암 환자에서 BCG를 이용한 면역요법연구. Keimyung Medical Journal, 7(1), 31–37.
Type
Article
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/14511
Appears in Collections:
2. Keimyung Medical Journal (계명의대 학술지) > 1988
1. School of Medicine (의과대학) > Dept. of Urology (비뇨의학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.